News

Published on 16 Feb 2024 on Insider Monkey via Yahoo Finance

Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript


Article preview image

Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript February 15, 2024

Alkermes plc misses on earnings expectations. Reported EPS is $0.22 EPS, expectations were $0.46. Alkermes plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Greetings. And welcome to the Alkermes Fourth Quarter 2023 Financial Results Conference Call. My name is Rob and I’ll be your operator for today’s call. All participant lines will be placed on mute to prevent background noise. [Operator Instructions] Please note that this conference is being recorded. I’ll now turn the call over to Sandy Coombs, Senior Vice President of Investor Relations and Corporate Affairs. Sandy, you may begin.

NASDAQ.ALKS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol ...

Zacks via Yahoo Finance 22 Apr 2024

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

For new and old investors, taking full advantage of the stock market and investing with confidenc...

Zacks via Yahoo Finance 16 Apr 2024

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

Alkermes plc ALKS announced positive top-line data from a phase Ib study evaluating its novel, in...

Zacks via Yahoo Finance 11 Apr 2024

Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term

For new and old investors, taking full advantage of the stock market and investing with confidenc...

Zacks via Yahoo Finance 10 Apr 2024

Alkermes stock gains on sleeping disorder drug (NASDAQ:ALKS)

Alkermes (ALKS) stock gains on positive Phase 1b trial results for the company's oral sleeping...

Seeking Alpha 9 Apr 2024

Alkermes' sleep drug shows promise in early trial By Investing.com

Alkermes plc (NASDAQ:ALKS) announced promising results from a phase 1b study of its investigation...

Investing.com 9 Apr 2024

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

For new and old investors, taking full advantage of the stock market and investing with confidenc...

Zacks via Yahoo Finance 25 Mar 2024

Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)

Alkermes PLC (NASDAQ:ALKS), a global biopharmaceutical company, is focused on developing innovati...

GuruFocus.com via Yahoo Finance 18 Mar 2024

Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript

Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript February 15, 2024 Alkermes plc misses...

Insider Monkey via Yahoo Finance 16 Feb 2024

Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates

Alkermes plc ALKS reported fourth-quarter 2023 adjusted earnings of 48 cents per share, which bea...

Zacks via Yahoo Finance 15 Feb 2024